Potentiation of Ethanol in Spatial Memory Deficits Induced by Some Benzodiazepines

Total Page:16

File Type:pdf, Size:1020Kb

Potentiation of Ethanol in Spatial Memory Deficits Induced by Some Benzodiazepines J Pharmacol Sci 101, 000 – 000 (2006) Journal of Pharmacological Sciences ©2006 The Japanese Pharmacological Society Full Paper Potentiation of Ethanol in Spatial Memory Deficits Induced by Some Benzodiazepines Atsushi Takiguchi1, Takayoshi Masuoka1, Yasuko Yamamoto1, Azusa Mikami1, and Chiaki Kamei1,* 1Department of Medicinal Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8530, Japan Received May 9, 2006; Accepted June 28, 2006 Abstract. Triazolam caused no significant increase in the total error at 0.05 and 0.1 mg/kg. However, at 0.2 mg/kg, it caused a significant increase in total error. Almost the same findings were observed with brotizolam and rilmazafone. That is, at 0.2 and 0.5 mg/kg of brotizolam, 0.5 and 1.0 mg/kg of rilmazafone caused no significant increase in the total error. However, brotizolam at 1.0 mg/kg and rilmazafone at 2.0 mg/kg caused a significant increase in total error. Triazolam (0.05 mg/kg) and ethanol (1.0 g/kg) showed no significant effect on the numbers of errors when used alone separately, but the simultaneous use of triazolam and ethanol caused a significant increase in total error. Almost the same findings were observed with the coadministration of brotizolam (0.2 mg/kg) or rilmazafone (0.5 mg/kg) with ethanol. These results clearly indicate that all the short-acting benzodiazepines used in the study showed potentiation by ethanol in spatial memory deficits in mice. Keywords: triazolam, brotizolam, rilmazafone, ethanol, radial maze Introduction in comparison with benzodiazepines alone, in human beings. For example, Seppala et al. (7) reported that the Benzodiazepines are widely used as a remedy for disturbance of short-term memory and learning induced insomnia. However, it is known that benzodiazepines by diazepam was potentiated by ethanol in humans. cause anterograde amnesia as a side effect (1, 2). In Moreover, Simpson and Rush (8) also found that ethanol addition, it has been reported that triazolodiazepines, exacerbated the memory deficit caused by temazepam in such as triazolam and brotizolam, caused retrograde an eight-digit number recall task and the repeated amnesia as well as anterograde amnesia in animals acquisition procedure in human beings. In the animal (3, 4). Noguchi et al. (5) reported that benzodiazepines, experiments, Kitaichi et al. (9) reported that ethanol such as triazolam and nitrazepam, impaired the spatial exacerbated the memory deficits by triazolam or chlor- memory learning, that is, acquisition on Morris water diazepoxide in the condition fear stress task in mice. maze in rats. On the other hand, White et al. (6) reported Shimizu et al. (10) also demonstrated that the combined that diazepam produced a spatial working memory use of triazolam with ethanol potently impaired the deficit on the retrieval process of six-arm maze perfor- spatial memory of the water maze task in rats. These mance in rats. These reports indicate that benzo- two reports dealt with the potentiation by ethanol in diazepines impaired both the acquisition process and the memory deficits by benzodiazepines in the acquisi- retrieval process of spatial memory performance. There- tion process. However, it is still unclear about the fore, particular attention has been directed at the clinical coadministration effect of benzodiazepines with ethanol use of benzodiazepines. on the retrieval process of spatial memory in animals. It is generally recognized that the combined use of In the present study, therefore, we examined the benzodiazepines and ethanol potentiates memory deficits, effects of some benzodiazepines on the retrieval process of spatial memory using an eight-arm radial maze in *Corresponding author. [email protected] mice, and we also investigated whether or not these Published online in J-STAGE: benzodiazepines-induced memory deficits are potentiated doi: 10.1254/jphs.FPJ06008X by ethanol. 1 2 A Takiguchi et al Materials and Methods as the total error. Running time per choice was defined as the total running time divided by the number of arm Animals choice. Male ddY mice, 6-week-old at the beginning of the experiment (body weight: 28 – 31 g; Nippon SLC, Data analysis Shizuoka) were used. All animals were maintained in Values shown are each a mean ± S.E.M. One-way an air-conditioned room with controlled temperature analysis of variance (ANOVA) with Dunnett’s test or (24 ± 2°C) and humidity (55 ± 15%). Body weight Mann-Whitney U test was used for statistical analysis of was kept at 80% – 90% of normal mice in the experi- the results of radial maze performance. ment. Water was provided ad libitum. All procedures involving animals were conducted in accordance with Results the Guidelines for Animal Experiments at Okayama University Advanced Science Research Center. Effects of benzodiazepines on radial maze performance Triazolam caused no significant increase in total Drugs error at doses of 0.05 and 0.1 mg/kg. However, at a dose The following drugs were used: triazolam (Halcion®; of 0.2 mg/kg, it caused a significant increase in total Pharmacia & Upjohn, London, UK), brotizolam error. Almost the same findings were observed with (Lendormin®; Nippon Boehringer Ingelheim, Hyogo), brotizolam and rilmazafone. That is, at smaller doses rilmazafone (Rhythmy®; Shionogi, Osaka), and ethanol (0.2 and 0.5 mg/kg of brotizolam and 0.5 and 1.0 mg/kg (99.5% (v/v); Sigma-Aldrich Japan, Tokyo). Triazolam, of rilmazafone), there was no significant increase in total brotizolam, and rilmazafone were suspended in 0.5% error. However, brotizolam at a dose of 1.0 mg/kg and (w/v) carboxymethyl cellulose solution. Ethanol was rilmazafone at a dose of 2.0 mg/kg caused a significant diluted with 0.5% carboxymethyl cellulose solution to a increase in total error (Fig. 1). concentration of 10% (w/v). Ethanol was administered orally 60 min before the test trial, and triazolam, Effect of ethanol on radial maze performance brotizolam, and rilmazafone were administered orally Ethanol at doses of 0.5 and 1.0 g/kg showed no 30 min before the test trial. significant effect on the total error (Fig. 2). Experimental apparatus and procedure Effects of simultaneous use of benzodiazepines and The apparatus used was as described in a previous ethanol on radial maze performance report (11). To familiarize the mouse with the radial Triazolam at a dose of 0.05 mg/kg, brotizolam at a maze, they received 1 daily habituation session for 2 dose of 0.2 mg/kg, and rilmazafone at a dose of days prior to training. On the first day, food pellets 0.5 mg/kg had no effect on the total number of errors (20 mg; Bio-Serv, A Holton Industries, Frenchtown, NJ, when used alone (Fig. 1). Therefore, these doses were USA) were scattered over the entire maze surface, and used to estimate the potentiation effect of ethanol on the four or five mice were simultaneously placed on the benzodiazepine-induced memory deficits. The simulta- radial maze and allowed to take pellets freely. On the neous use of triazolam at a dose of 0.05 mg/kg and next day, a pellet was placed in the food cup in each of ethanol at a dose of 1.0 g/kg caused a significant the eight arms, and the mouse was allowed to explore increase in total error in comparison with triazolam at a freely until it had taken all the pellets. After adaptation, dose of 0.05 mg/kg alone or ethanol at a dose of all mice were trained with two trials per day. In each 1.0 g/kg alone. Almost the same findings were observed trial, only four arms were baited, and the sequence was with brotizolam, that is, at a dose of 0.2 mg/kg or not changed throughout the experiment. The mouse rilmazafone at a dose of 0.5 mg/kg with ethanol showed was placed on the center platform, which was closed off a significant potentiation of total error in comparison by a door. After 20 s, the door was opened and the mouse with brotizolam, rilmazafone, or ethanol alone (Fig. 3). was allowed to make an arm choice to obtain food pellets until all four pellets had been eaten or 10 min Effects of simultaneous use of benzodiazepines and had elapsed. Mice were trained until reaching a criterion ethanol on running time per choice of at most one error per trial for five successive trials. No significant changes were observed with running Test trials were carried out the next day after reaching time per choice used as an index of locomotor activity the criterion. After the drugs administration, test trials in mice after the simultaneous use of these benzo- were performed in the same manner as training trials. diazepines and ethanol compared with benzodiazepines The number of entries into the unbaited arms was scored alone or ethanol alone (Fig. 4). Potentiation of Ethanol and Benzodiazepines 3 Fig. 3. Effects of simultaneous use of benzodiazepines and ethanol on radial maze performance in mice. Ethanol was administered orally 60 min before the test trial; and triazolam, brotizolam, and rilmazafone were administered orally 30 min before the test trials. Column and vertical bars represent means ± S.E.M. (n = 11 – 14). *P<0.05, as compared with the benzodiazepine-treated group. #P<0.05, as compared with the ethanol-treated group. Fig. 1. Effects of benzodiazepines on radial maze performance in mice. Mice showing no or one error per trial for five successive trials were used in the test. Benzodiazepines were administered orally Fig. 4. Effects of simultaneous use of benzodiazepines and ethanol 30 min before the test trial. Column and vertical bars represent on running time per choice.
Recommended publications
  • Analytical Methods for Determination of Benzodiazepines. a Short Review
    Cent. Eur. J. Chem. • 12(10) • 2014 • 994-1007 DOI: 10.2478/s11532-014-0551-1 Central European Journal of Chemistry Analytical methods for determination of benzodiazepines. A short review Review Article Paulina Szatkowska1, Marcin Koba1*, Piotr Kośliński1, Jacek Wandas1, Tomasz Bączek2,3 1Department of Toxicology, Faculty of Pharmacy, Collegium Medicum of Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland 3Institute of Health Sciences, Division of Human Anatomy and Physiology, Pomeranian University of Słupsk, 76-200 Słupsk, Poland Received 16 July 2013; Accepted 6 February 2014 Abstract: Benzodiazepines (BDZs) are generally commonly used as anxiolytic and/or hypnotic drugs as a ligand of the GABAA-benzodiazepine receptor. Moreover, some of benzodiazepines are widely used as an anti-depressive and sedative drugs, and also as anti-epileptic drugs and in some cases can be useful as an adjunct treatment in refractory epilepsies or anti-alcoholic therapy. High-performance liquid chromatography (HPLC) methods, thin-layer chromatography (TLC) methods, gas chromatography (GC) methods, capillary electrophoresis (CE) methods and some of spectrophotometric and spectrofluorometric methods were developed and have been extensively applied to the analysis of number of benzodiazepine derivative drugs (BDZs) providing reliable and accurate results. The available chemical methods for the determination of BDZs in biological materials and pharmaceutical formulations are reviewed in this work. Keywords: Analytical methods • Benzodiazepines • Drugs analysis • Pharmaceutical formulations © Versita Sp. z o.o. 1. Introduction and long). For this reason, an application of these drugs became broader allowing their utility to a larger extent, Benzodiazepines have been first introduced into medical and at the same time, problems related to drug abuse practice in the 60s of the last century.
    [Show full text]
  • Comparative Efficacy and Acceptability of Pharmacological Treatments for Insomnia in Adults: a Systematic Review and Network Meta-Analysis (Protocol)
    Cochrane Database of Systematic Reviews Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis (Protocol) De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L. Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-anal- ysis. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD012364. DOI: 10.1002/14651858.CD012364. www.cochranelibrary.com Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta- analysis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 4 METHODS ...................................... 4 Figure1. ..................................... 5 ACKNOWLEDGEMENTS . 9 REFERENCES ..................................... 10 APPENDICES ..................................... 14 WHAT’SNEW..................................... 18 CONTRIBUTIONSOFAUTHORS . 18 DECLARATIONSOFINTEREST . 18 Comparative efficacy and acceptability of pharmacological treatments for
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Report on the Investigation Results
    Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Report on the Investigation Results February 28, 2017 Pharmaceuticals and Medical Devices Agency I. Overview of Product [Non-proprietary name] See Attachment 1 [Brand name] See Attachment 1 [Approval holder] See Attachment 1 [Indications] See Attachment 1 [Dosage and administration] See Attachment 1 [Investigating office] Office of Safety II 1 Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. II. Background of the investigation 1. Status in Japan Hypnotics and anxiolytics are prescribed by various specialties and widely used in clinical practice. In particular, benzodiazepine (BZ) receptor agonists, which act on BZ receptors, bind to gamma-aminobutyric acid (GABA)A-BZ receptor complex and enhance the function of GABAA receptors. This promotes neurotransmission of inhibitory systems and demonstrates hypnotic/sedative effects, anxiolytic effects, muscle relaxant effects, and antispasmodic effects. Since the approval of chlordiazepoxide in March 1961, many BZ receptor agonists have been approved as hypnotics and anxiolytics. Currently, hypnotics and anxiolytics are causative agents of drug-related disorders such as drug dependence in Japanese clinical practice. Hypnotics and anxiolitics that rank high in causative agents are BZ receptor agonists for which high frequencies of high doses and multidrug prescriptions have been reported (Japanese Journal of Clinical Psychopharmacology 2013; 16(6): 803-812, Modern Physician 2014; 34(6): 653-656, etc.).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Title Continuation and Discontinuation of Benzodiazepine Prescriptions: A
    Continuation and discontinuation of benzodiazepine Title prescriptions: A cohort study based on a large claims database in Japan( Dissertation_全文 ) Author(s) Takeshima, Nozomi Citation 京都大学 Issue Date 2016-05-23 URL https://doi.org/10.14989/doctor.k19890 Right Type Thesis or Dissertation Textversion ETD Kyoto University Psychiatry Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎ Contents lists available at ScienceDirect Psychiatry Research journal homepage: www.elsevier.com/locate/psychres Continuation and discontinuation of benzodiazepine prescriptions: A cohort study based on A large claims database in Japan Nozomi Takeshima, Yusuke Ogawa, Yu Hayasaka, Toshi A Furukawa n Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan article info abstract Article history: Although benzodiazepines (BZDs) are often prescribed to treat a wide range of psychiatric and neuro- Received 29 March 2015 logical conditions, they are also associated with various harms and risks including dependence. However Received in revised form the frequency of its continued use in the real world has not been well studied, especially at longer follow- 15 October 2015 ups. The aim of this study was to clarify the frequency of long-term BZD use among new BZD users over Accepted 15 January 2016 longer follow-ups and to identify its predictors. We conducted a cohort study to examine how frequently new BZD users became chronic users, based on a large claims database in Japan from January 2005 to Keywords: June 2014. We used Cox proportional hazards models to identify potential predictors. A total 84,412 Benzodiazepine patients with new BZD prescriptions were included in our cohort.
    [Show full text]
  • PMDA Alert for Proper Use of Drugs When Using Benzodiazepine
    ■ PMDA Alert for Proper Use of Drugs https://www.pmda.go.jp/english/safety/info-services/drugs/properly- No. 11 March 2017 use-alert/0001.html PMDA Alert for Proper Use of Drugs Pharmaceuticals and Medical Devices Agency No. 11 March 2017 Dependence associated with Benzodiazepine Receptor Agonists [To Patients] This document is for healthcare professionals. If taking the drug, please consult with your physicians or pharmacists. Please don’t reduce the dosage or stop taking the drug on self-judgment. Benzodiazepine receptor agonists have a characteristic of developing physical dependence with long-term use even within an approved dose range, leading to various withdrawal symptoms on dose reduction or discontinuation. <Major withdrawal symptoms> insomnia, anxiety, feeling irritated, headache, queasy/vomiting, delirium, tremor, seizure, etc. Please pay careful attention to the following when using benzodiazepine receptor agonists as hypnotics-sedatives and anxiolytics. Healthcare professionals should avoid long-term use with chronic administration. - Dependence may occur with long-term use even within an approved dose range. - Therapeutic necessity should be carefully considered when continuing administration of the drug. Healthcare professionals should adhere to the dosage and confirm that there is no multiple prescription of similar drugs. - Long-term administration, high-dose administration, or multiple medications increase the risk of developing dependence. - Healthcare professionals should confirm that similar drugs are not prescribed by other medical institutions. Healthcare professionals should reduce the dose or discontinue carefully such as by gradual dose reduction or alternate-days administration when discontinuing the administration. - Sudden discontinuation will develop serious withdrawal symptoms in addition to aggravate primary diseases.
    [Show full text]
  • GABA Receptor Gamma-Aminobutyric Acid Receptor; Γ-Aminobutyric Acid Receptor
    GABA Receptor Gamma-aminobutyric acid Receptor; γ-Aminobutyric acid Receptor GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABAB receptors are G protein-coupled receptors (also known asmetabotropic receptors). It has long been recognized that the fast response of neurons to GABA that is blocked by bicuculline and picrotoxin is due to direct activation of an anion channel. This channel was subsequently termed the GABAA receptor. Fast-responding GABA receptors are members of family of Cys-loop ligand-gated ion channels. A slow response to GABA is mediated by GABAB receptors, originally defined on the basis of pharmacological properties. www.MedChemExpress.com 1 GABA Receptor Agonists, Antagonists, Inhibitors, Activators & Modulators (+)-Bicuculline (+)-Kavain (d-Bicuculline) Cat. No.: HY-N0219 Cat. No.: HY-B1671 (+)-Bicuculline is a light-sensitive competitive (+)-Kavain, a main kavalactone extracted from Piper antagonist of GABA-A receptor. methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels. Purity: 99.97% Purity: 99.98% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg (-)-Bicuculline methobromide (-)-Bicuculline methochloride (l-Bicuculline methobromide) Cat. No.: HY-100783 (l-Bicuculline methochloride) Cat. No.: HY-100783A (-)-Bicuculline methobromide (l-Bicuculline (-)-Bicuculline methochloride (l-Bicuculline methobromide) is a potent GABAA receptor methochloride) is a potent GABAA receptor antagonist.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • The Prevalence and Patterns of Combined Psychotropic Polypharmacy Among Acute
    bioRxiv preprint doi: https://doi.org/10.1101/649012; this version posted May 24, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. The Prevalence and Patterns of Combined Psychotropic Polypharmacy among Acute Care Hospitals in Japan Sayuri Shimizu,1 Yasuyuki Okumura,2 Koichi B. Ishikawa,3 Shinya Matsuda,4 Hiroto Ito,5 Kiyohide Fushimi6 1 Institute for Health Economics and Policy, Japan 2 Tokyo Metropolitan Institute of Medical Science 3 International University of Health and Welfare, Japan 4 University of Occupational and Environmental Health, Kitakyushu, Japan 5 National Institute of Occupational Safety and Health, Japan, Japan 6 Tokyo Medical and Dental University Graduate School of Medicine, Japan ABSTRACT Purpose To evaluate the prescribing patterns of psychotropic polypharmacy for inpatients of acute care hospitals in Japan. Methods Administrative data on 2,639,885 patients admitted to acute care hospitals in Japan between July and December of 2008 were analyzed retrospectively. We defined psychotropic medications as antipsychotics, antidepressants, benzodiazepines, and other sedatives/hypnotics and studied their prescription patterns during the hospitalization of patients with stroke, acute cardiac infarction, cancer, and diabetes mellitus. Results At least one psychotropic drug was prescribed in 35.9% of all cases. Two-drug combinations of antipsychotic drugs were prescribed for stroke patients in 14,615 cases (1.4%), more than 2 in 3,132 cases (0.3%), and 22.4% of cases were prescribed 2 or more psychotropic drugs in addition to antipsychotic drugs.
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • List of Benzodiazepines - Wikipedia, the Free Encyclopedia
    List of benzodiazepines - Wikipedia, the free encyclopedia Log in / create account Article Talk Read Edit Our updated Terms of Use will become effective on May 25, 2012. Find out more. List of benzodiazepines From Wikipedia, the free encyclopedia Main page The below tables contain a list of benzodiazepines that Benzodiazepines Contents are commonly prescribed, with their basic pharmacological Featured content characteristics such as half-life and equivalent doses to other Current events benzodiazepines also listed, along with their trade names and Random article primary uses. The elimination half-life is how long it takes for Donate to Wikipedia half of the drug to be eliminated by the body. "Time to peak" Interaction refers to when maximum levels of the drug in the blood occur Help after a given dose. Benzodiazepines generally share the About Wikipedia same pharmacological properties, such as anxiolytic, Community portal sedative, hypnotic, skeletal muscle relaxant, amnesic and Recent changes anticonvulsant (hypertension in combination with other anti The core structure of benzodiazepines. Contact Wikipedia hypertension medications). Variation in potency of certain "R" labels denote common locations of effects may exist among individual benzodiazepines. Some side chains, which give different Toolbox benzodiazepines produce active metabolites. Active benzodiazepines their unique properties. Print/export metabolites are produced when a person's body metabolizes Benzodiazepine the drug into compounds that share a similar pharmacological
    [Show full text]